All In Biotech

Drug Trial Radar · NCT05067140

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

A Phase 1/2 Open-Label, Dose-Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 Monotherapy and in Combination With Abiraterone in Patients With Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

164

Actual

Start

Sep 2, 2021

Primary completion

May 25, 2027

Study completion May 25, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human, Phase 1/2, open-label study evaluates the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of JSB462 (luxdegalutamide, previously ARV-766) administered as monotherapy and in combination with abiraterone in participants with metastatic prostate cancer. The study includes dose-escalation and cohort expansion components to determine the recommended Phase 2 dose and assess clinical activity.

Conditions

  • Prostate Cancer Metastatic

Interventions

  • ARV-766Drug

    Parts A and C: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment. Part B: 100mg or 300mg oral tablet(s) once daily in 28 day cycles.

  • AbirateroneDrug

    Abiraterone is administered orally in combination with ARV-766, typically on an empty stomach with water, in accordance with prescribing information and standard clinical practice.

  • Corticosteroid (e.g., prednisone/prednisolone)Drug

    Prednisone or prednisolone was administered in accordance with local prescribing information during treatment with abiraterone acetate.

  • Androgen Deprivation Therapy (ADT)Other

    Ongoing androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or prior orchiectomy, is maintained per investigator choice or patient preference.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Up to 28 days
  2. Part C: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatmentTime frame: Up to 28 Days
  3. Parts A and C: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose through approximately 30 days after last dose
  4. Parts A and C: Incidence of laboratory abnormalitiesTime frame: From first dose through approximately 30 days after last dose
  5. Part B: Prostate-Specific Antigen 30% Response Rate (PSA30)Time frame: 12 Weeks
  6. Part B: Prostate-Specific Antigen 50% Response Rate (PSA50)Time frame: 12 Weeks

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical

    Duarte, California

  • University of California San Diego - Moores Cancer Center

    La Jolla, California

  • Providence Saint Johns Health Ctr

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Chesapeake Urology Associates

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Univ of Pittsburgh Cancer Inst

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Urology San Antonio

    San Antonio, Texas

  • University of Virginia Medical Center

    Charlottesville, Virginia

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Wisconsin Paul P Carbone Comp Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.